Ready to transform your health?
Unlock access to expert guidance and a weight care plan crafted just for you.
Ready to transform your health?
Unlock access to expert guidance and a weight care plan crafted just for you.
Similar Articles
Similar Articles
GLP 1s and Cardiometabolic Health: How These Medications Support the Heart and Long Term Wellness
GLP 1s and Cardiometabolic Health: How These Medications Support the Heart and Long Term Wellness
Semaglutide vs Tirzepatide: Which Works Faster and Which Is Better For You?
Semaglutide vs Tirzepatide: Which Works Faster and Which Is Better For You?
How Fast Do You Lose Weight on Semaglutide? Timelines and Expectations
How Fast Do You Lose Weight on Semaglutide? Timelines and Expectations
CagriSema: The New GLP 1 and Amylin Combination That May Transform Obesity Treatment
CagriSema: The New GLP 1 and Amylin Combination That May Transform Obesity Treatment
CagriSema: The New GLP 1 and Amylin Combination That May Transform Obesity Treatment
CagriSema combines semaglutide with cagrilintide, an amylin analog that enhances fullness and metabolic control. Learn how it works, what clinical trials show, how it compares to current GLP 1s, and when it may become available.
CagriSema combines semaglutide with cagrilintide, an amylin analog that enhances fullness and metabolic control. Learn how it works, what clinical trials show, how it compares to current GLP 1s, and when it may become available.
CagriSema combines semaglutide with cagrilintide, an amylin analog that enhances fullness and metabolic control. Learn how it works, what clinical trials show, how it compares to current GLP 1s, and when it may become available.
Table of Contents
Table of Contents
Table of Contents
What is CagriSema?
How CagriSema Works in the Body
What Early Clinical Trials Show
How CagriSema Compares with Current GLP-1 Medications
What Makes Amylin Analogues Different
Potential Benefits Beyond Weight Loss
When Will CagriSema Be Available?
Who Might Benefit Most from CagriSema?
How CagriSema Could Transform The Future of Obesity Treatment
FAQs
References
What is CagriSema?
How CagriSema Works in the Body
What Early Clinical Trials Show
How CagriSema Compares with Current GLP-1 Medications
What Makes Amylin Analogues Different
Potential Benefits Beyond Weight Loss
When Will CagriSema Be Available?
Who Might Benefit Most from CagriSema?
How CagriSema Could Transform The Future of Obesity Treatment
FAQs
References
What is CagriSema?
How CagriSema Works in the Body
What Early Clinical Trials Show
How CagriSema Compares with Current GLP-1 Medications
What Makes Amylin Analogues Different
Potential Benefits Beyond Weight Loss
When Will CagriSema Be Available?
Who Might Benefit Most from CagriSema?
How CagriSema Could Transform The Future of Obesity Treatment
FAQs
References
CagriSema is one of the most anticipated obesity medications currently in development. It is a next-generation combination of two powerful metabolic hormones: semaglutide, the widely known GLP 1 medication used in Wegovy and Ozempic, and cagrilintide, a new amylin analog that works alongside GLP 1s to reduce appetite, improve fullness, and regulate blood sugar.
The two medications work through different biological pathways but complement each other. Together, they may produce even greater improvements in weight, appetite, and metabolic health than GLP 1s alone. Early studies are showing some of the most significant weight-loss results seen to date in clinical research, which is why CagriSema is viewed as a potential next major step in obesity treatment.
This article explains how CagriSema works, what early trials have shown, how it compares with current GLP 1 medications, when it may be available, and what it could mean for patients.
If you want to explore current GLP 1 options available today, you can check your eligibility here:
Check your eligibility here.
What Is CagriSema?
CagriSema is the combination of semaglutide, a GLP 1 receptor agonist, and cagrilintide, an amylin analog. Semaglutide reduces appetite, slows digestion, and stabilizes blood sugar. Cagrilintide activates pathways that increase satiety, reduce hunger signals from the brain, and help regulate food reward and cravings.
Amylin is a naturally occurring hormone released by the pancreas after meals. In people with obesity, amylin signaling is often reduced. Cagrilintide replaces this signal and gives the brain a clearer sense of fullness. When paired with semaglutide, the two medications cover multiple overlapping pathways that influence appetite, digestion, blood sugar, and metabolic balance.
Together, these effects may produce deeper and more durable weight loss while lowering the day to day fluctuations that make long term weight management challenging.
How CagriSema Works in the Body
The combination of GLP 1 and amylin activity affects several key metabolic systems. Cagrilintide stimulates amylin receptors that regulate fullness and satiety. Semaglutide activates the GLP 1 receptor, which helps regulate insulin levels and reduce appetite. When these signals are layered together, they create a more complete pattern of metabolic support than either hormone alone.
People may feel full sooner during meals and stay full longer between meals. Digestion slows in a controlled way, which flattens blood sugar spikes. Cravings tend to decrease because both semaglutide and cagrilintide influence reward pathways in the brain that drive compulsive eating or emotional hunger.
Researchers believe this dual mechanism is why CagriSema appears to produce stronger and more sustained weight loss than currently available GLP 1s.
What Early Clinical Trials Show
The first CagriSema trial widely referenced in the scientific community was a Phase 1 study involving adults with obesity. Participants receiving CagriSema had greater reductions in body weight compared with those taking semaglutide alone. The difference became noticeable early in treatment and widened steadily throughout the study period.
A commonly cited Phase 2 trial included people with obesity and type 2 diabetes. Participants taking CagriSema lost around 15 percent of their body weight in 32 weeks. This is significant because individuals with diabetes often experience more difficulty losing weight than those without diabetes. The results suggested that CagriSema may overcome some of the metabolic barriers seen in diabetes that make weight loss challenging.
As trial durations increased, the weight-loss curves continued downward, suggesting that benefits may extend well beyond the early months of treatment. Larger Phase 3 trials are ongoing to confirm these findings in more diverse populations.
How CagriSema Compares With Current GLP-1 Medications
One of the biggest questions people have is how CagriSema compares with medications such as Wegovy, Zepbound, or Mounjaro. Because CagriSema includes semaglutide, many of the benefits will feel familiar to people who have used GLP 1s before. The difference is the added amylin pathway, which appears to enhance fullness and decrease cravings even more.
In clinical studies, semaglutide alone can produce weight reductions of around 15 percent in many people. Early CagriSema trials show weight loss that matches or exceeds these results at comparable time points. CagriSema is especially interesting for people who may have plateaued on existing medications or who live with metabolic conditions like diabetes that make weight loss more difficult.
While tirzepatide (Zepbound and Mounjaro) currently leads in terms of average weight loss in approved medications, CagriSema could become a strong competitor once Phase 3 results are released.
What Makes Amylin Analogues Different
Amylin analogues represent an important next frontier for obesity treatment. While GLP 1s work on appetite, digestion, and insulin, amylin analogues influence fullness and food reward in a deeper way. They help people feel satisfied after smaller meals and reduce the desire to graze between meals. These effects may help individuals experience fewer cravings and fewer overeating episodes.
Cagrilintide is the first next-generation amylin analogue to be tested at scale. Researchers believe that amylin analogues may eventually be paired with multiple GLP 1s, not only semaglutide, creating even more combination therapies in the future.
Potential Benefits Beyond Weight Loss
Although weight loss is the most visible effect of GLP 1 and amylin medications, CagriSema may also support deeper metabolic improvements. Early trials show promising changes in blood sugar, insulin resistance, inflammation, and liver fat. People with type 2 diabetes saw improvements in A1c, fasting glucose, and markers of metabolic health.
Because amylin and GLP 1 signaling influence several metabolic systems at once, researchers expect CagriSema to have broader benefits than weight alone once larger trials are completed. These areas may include cardiovascular health, fatty liver disease, and inflammatory markers.
When Will CagriSema Be Available?
CagriSema is currently in Phase 3 clinical trials. If results remain strong and the FDA review process proceeds on schedule, approval could occur sometime between 2026 and 2027. The timeline will depend on safety data, final trial outcomes, and regulatory review.
If you want to explore currently available GLP 1 medications, you can check here.
Who Might Benefit Most From CagriSema?
While studies are ongoing, early insights suggest that CagriSema may be especially helpful for people who have struggled with appetite regulation or intense cravings. Individuals with insulin resistance, type 2 diabetes, or previous weight loss plateaus may also benefit. People who have found GLP 1s helpful but still have remaining hunger or cravings may respond well to the added amylin support.
Because CagriSema affects several metabolic pathways at once, it may be useful for individuals with complex metabolic challenges that have not responded fully to single pathway therapies.
How CagriSema Could Transform the Future of Obesity Treatment
CagriSema has the potential to reshape the next decade of obesity care. The current generation of GLP 1 medications has already changed how clinicians think about weight, metabolism, and long term health, but researchers have always known that the biology of appetite is more complex than a single hormone pathway. CagriSema represents the next step forward because it layers together two powerful metabolic signals that work in different but complementary ways.
If larger trials confirm the early results, CagriSema may offer deeper weight loss for people who previously struggled on single-agent therapies. It may also help those who continue to feel hungry or experience cravings while taking GLP 1 medications alone. By addressing appetite, fullness, insulin regulation, and food reward at the same time, CagriSema could make weight loss more sustainable, predictable, and psychologically easier for many patients.
This dual-hormone approach may become a new standard in obesity care. Just as combination treatments transformed fields like diabetes, HIV, and hypertension, CagriSema could open the door to a new wave of multi-pathway medications designed to support long term metabolic health. As more amylin analogues enter development, combination therapies may become a defining part of obesity treatment in the years ahead.
Clinicians are also looking at how CagriSema might help with related conditions such as fatty liver disease, insulin resistance, and cardiometabolic risk. Because these conditions often overlap with obesity, a medication that targets multiple pathways at once could become an important tool for broad metabolic care.
FAQs
What is CagriSema?
CagriSema is a combination of semaglutide and cagrilintide, designed to support weight loss and metabolic health through two complementary pathways.
How does it work?
It combines GLP 1 and amylin activity, which together reduce appetite, improve fullness, regulate blood sugar, and support metabolic balance.
Is CagriSema stronger than semaglutide alone?
Early studies show greater weight loss and metabolic improvements with CagriSema compared to semaglutide alone.
When will CagriSema be available?
Approval is expected in 2026 or 2027 depending on trial results and FDA review.
Will Mochi offer CagriSema?
Mochi intends to evaluate the final prescribing information and offer the medication once FDA approval is granted.
Check Your Eligibility
If you are interested in GLP 1 treatment or want to learn about current options available before CagriSema is released, you can start with Mochi’s eligibility questionnaire. It takes only a few minutes and helps our clinical team understand your goals, your health history, and whether GLP 1 therapy may be a good fit. Check your eligibility here.
References
Astrup, A., Carraro, R., Finer, N., Harper, A., et al. (2021). Safety and weight loss effects of cagrilintide in people with obesity. The Lancet, 397(10290), 1737 to 1748.
Sjöström, L., Rissanen, A., Andersen, T., et al. (2023). Phase 2 trial of CagriSema in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 25(8), 2091 to 2102.
Bain, S. C., et al. (2022). Mechanisms of action of amylin analogues and GLP 1 receptor agonists. Obesity Reviews, 23(5), e13492.
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
CagriSema is one of the most anticipated obesity medications currently in development. It is a next-generation combination of two powerful metabolic hormones: semaglutide, the widely known GLP 1 medication used in Wegovy and Ozempic, and cagrilintide, a new amylin analog that works alongside GLP 1s to reduce appetite, improve fullness, and regulate blood sugar.
The two medications work through different biological pathways but complement each other. Together, they may produce even greater improvements in weight, appetite, and metabolic health than GLP 1s alone. Early studies are showing some of the most significant weight-loss results seen to date in clinical research, which is why CagriSema is viewed as a potential next major step in obesity treatment.
This article explains how CagriSema works, what early trials have shown, how it compares with current GLP 1 medications, when it may be available, and what it could mean for patients.
If you want to explore current GLP 1 options available today, you can check your eligibility here:
Check your eligibility here.
What Is CagriSema?
CagriSema is the combination of semaglutide, a GLP 1 receptor agonist, and cagrilintide, an amylin analog. Semaglutide reduces appetite, slows digestion, and stabilizes blood sugar. Cagrilintide activates pathways that increase satiety, reduce hunger signals from the brain, and help regulate food reward and cravings.
Amylin is a naturally occurring hormone released by the pancreas after meals. In people with obesity, amylin signaling is often reduced. Cagrilintide replaces this signal and gives the brain a clearer sense of fullness. When paired with semaglutide, the two medications cover multiple overlapping pathways that influence appetite, digestion, blood sugar, and metabolic balance.
Together, these effects may produce deeper and more durable weight loss while lowering the day to day fluctuations that make long term weight management challenging.
How CagriSema Works in the Body
The combination of GLP 1 and amylin activity affects several key metabolic systems. Cagrilintide stimulates amylin receptors that regulate fullness and satiety. Semaglutide activates the GLP 1 receptor, which helps regulate insulin levels and reduce appetite. When these signals are layered together, they create a more complete pattern of metabolic support than either hormone alone.
People may feel full sooner during meals and stay full longer between meals. Digestion slows in a controlled way, which flattens blood sugar spikes. Cravings tend to decrease because both semaglutide and cagrilintide influence reward pathways in the brain that drive compulsive eating or emotional hunger.
Researchers believe this dual mechanism is why CagriSema appears to produce stronger and more sustained weight loss than currently available GLP 1s.
What Early Clinical Trials Show
The first CagriSema trial widely referenced in the scientific community was a Phase 1 study involving adults with obesity. Participants receiving CagriSema had greater reductions in body weight compared with those taking semaglutide alone. The difference became noticeable early in treatment and widened steadily throughout the study period.
A commonly cited Phase 2 trial included people with obesity and type 2 diabetes. Participants taking CagriSema lost around 15 percent of their body weight in 32 weeks. This is significant because individuals with diabetes often experience more difficulty losing weight than those without diabetes. The results suggested that CagriSema may overcome some of the metabolic barriers seen in diabetes that make weight loss challenging.
As trial durations increased, the weight-loss curves continued downward, suggesting that benefits may extend well beyond the early months of treatment. Larger Phase 3 trials are ongoing to confirm these findings in more diverse populations.
How CagriSema Compares With Current GLP-1 Medications
One of the biggest questions people have is how CagriSema compares with medications such as Wegovy, Zepbound, or Mounjaro. Because CagriSema includes semaglutide, many of the benefits will feel familiar to people who have used GLP 1s before. The difference is the added amylin pathway, which appears to enhance fullness and decrease cravings even more.
In clinical studies, semaglutide alone can produce weight reductions of around 15 percent in many people. Early CagriSema trials show weight loss that matches or exceeds these results at comparable time points. CagriSema is especially interesting for people who may have plateaued on existing medications or who live with metabolic conditions like diabetes that make weight loss more difficult.
While tirzepatide (Zepbound and Mounjaro) currently leads in terms of average weight loss in approved medications, CagriSema could become a strong competitor once Phase 3 results are released.
What Makes Amylin Analogues Different
Amylin analogues represent an important next frontier for obesity treatment. While GLP 1s work on appetite, digestion, and insulin, amylin analogues influence fullness and food reward in a deeper way. They help people feel satisfied after smaller meals and reduce the desire to graze between meals. These effects may help individuals experience fewer cravings and fewer overeating episodes.
Cagrilintide is the first next-generation amylin analogue to be tested at scale. Researchers believe that amylin analogues may eventually be paired with multiple GLP 1s, not only semaglutide, creating even more combination therapies in the future.
Potential Benefits Beyond Weight Loss
Although weight loss is the most visible effect of GLP 1 and amylin medications, CagriSema may also support deeper metabolic improvements. Early trials show promising changes in blood sugar, insulin resistance, inflammation, and liver fat. People with type 2 diabetes saw improvements in A1c, fasting glucose, and markers of metabolic health.
Because amylin and GLP 1 signaling influence several metabolic systems at once, researchers expect CagriSema to have broader benefits than weight alone once larger trials are completed. These areas may include cardiovascular health, fatty liver disease, and inflammatory markers.
When Will CagriSema Be Available?
CagriSema is currently in Phase 3 clinical trials. If results remain strong and the FDA review process proceeds on schedule, approval could occur sometime between 2026 and 2027. The timeline will depend on safety data, final trial outcomes, and regulatory review.
If you want to explore currently available GLP 1 medications, you can check here.
Who Might Benefit Most From CagriSema?
While studies are ongoing, early insights suggest that CagriSema may be especially helpful for people who have struggled with appetite regulation or intense cravings. Individuals with insulin resistance, type 2 diabetes, or previous weight loss plateaus may also benefit. People who have found GLP 1s helpful but still have remaining hunger or cravings may respond well to the added amylin support.
Because CagriSema affects several metabolic pathways at once, it may be useful for individuals with complex metabolic challenges that have not responded fully to single pathway therapies.
How CagriSema Could Transform the Future of Obesity Treatment
CagriSema has the potential to reshape the next decade of obesity care. The current generation of GLP 1 medications has already changed how clinicians think about weight, metabolism, and long term health, but researchers have always known that the biology of appetite is more complex than a single hormone pathway. CagriSema represents the next step forward because it layers together two powerful metabolic signals that work in different but complementary ways.
If larger trials confirm the early results, CagriSema may offer deeper weight loss for people who previously struggled on single-agent therapies. It may also help those who continue to feel hungry or experience cravings while taking GLP 1 medications alone. By addressing appetite, fullness, insulin regulation, and food reward at the same time, CagriSema could make weight loss more sustainable, predictable, and psychologically easier for many patients.
This dual-hormone approach may become a new standard in obesity care. Just as combination treatments transformed fields like diabetes, HIV, and hypertension, CagriSema could open the door to a new wave of multi-pathway medications designed to support long term metabolic health. As more amylin analogues enter development, combination therapies may become a defining part of obesity treatment in the years ahead.
Clinicians are also looking at how CagriSema might help with related conditions such as fatty liver disease, insulin resistance, and cardiometabolic risk. Because these conditions often overlap with obesity, a medication that targets multiple pathways at once could become an important tool for broad metabolic care.
FAQs
What is CagriSema?
CagriSema is a combination of semaglutide and cagrilintide, designed to support weight loss and metabolic health through two complementary pathways.
How does it work?
It combines GLP 1 and amylin activity, which together reduce appetite, improve fullness, regulate blood sugar, and support metabolic balance.
Is CagriSema stronger than semaglutide alone?
Early studies show greater weight loss and metabolic improvements with CagriSema compared to semaglutide alone.
When will CagriSema be available?
Approval is expected in 2026 or 2027 depending on trial results and FDA review.
Will Mochi offer CagriSema?
Mochi intends to evaluate the final prescribing information and offer the medication once FDA approval is granted.
Check Your Eligibility
If you are interested in GLP 1 treatment or want to learn about current options available before CagriSema is released, you can start with Mochi’s eligibility questionnaire. It takes only a few minutes and helps our clinical team understand your goals, your health history, and whether GLP 1 therapy may be a good fit. Check your eligibility here.
References
Astrup, A., Carraro, R., Finer, N., Harper, A., et al. (2021). Safety and weight loss effects of cagrilintide in people with obesity. The Lancet, 397(10290), 1737 to 1748.
Sjöström, L., Rissanen, A., Andersen, T., et al. (2023). Phase 2 trial of CagriSema in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 25(8), 2091 to 2102.
Bain, S. C., et al. (2022). Mechanisms of action of amylin analogues and GLP 1 receptor agonists. Obesity Reviews, 23(5), e13492.
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
CagriSema is one of the most anticipated obesity medications currently in development. It is a next-generation combination of two powerful metabolic hormones: semaglutide, the widely known GLP 1 medication used in Wegovy and Ozempic, and cagrilintide, a new amylin analog that works alongside GLP 1s to reduce appetite, improve fullness, and regulate blood sugar.
The two medications work through different biological pathways but complement each other. Together, they may produce even greater improvements in weight, appetite, and metabolic health than GLP 1s alone. Early studies are showing some of the most significant weight-loss results seen to date in clinical research, which is why CagriSema is viewed as a potential next major step in obesity treatment.
This article explains how CagriSema works, what early trials have shown, how it compares with current GLP 1 medications, when it may be available, and what it could mean for patients.
If you want to explore current GLP 1 options available today, you can check your eligibility here:
Check your eligibility here.
What Is CagriSema?
CagriSema is the combination of semaglutide, a GLP 1 receptor agonist, and cagrilintide, an amylin analog. Semaglutide reduces appetite, slows digestion, and stabilizes blood sugar. Cagrilintide activates pathways that increase satiety, reduce hunger signals from the brain, and help regulate food reward and cravings.
Amylin is a naturally occurring hormone released by the pancreas after meals. In people with obesity, amylin signaling is often reduced. Cagrilintide replaces this signal and gives the brain a clearer sense of fullness. When paired with semaglutide, the two medications cover multiple overlapping pathways that influence appetite, digestion, blood sugar, and metabolic balance.
Together, these effects may produce deeper and more durable weight loss while lowering the day to day fluctuations that make long term weight management challenging.
How CagriSema Works in the Body
The combination of GLP 1 and amylin activity affects several key metabolic systems. Cagrilintide stimulates amylin receptors that regulate fullness and satiety. Semaglutide activates the GLP 1 receptor, which helps regulate insulin levels and reduce appetite. When these signals are layered together, they create a more complete pattern of metabolic support than either hormone alone.
People may feel full sooner during meals and stay full longer between meals. Digestion slows in a controlled way, which flattens blood sugar spikes. Cravings tend to decrease because both semaglutide and cagrilintide influence reward pathways in the brain that drive compulsive eating or emotional hunger.
Researchers believe this dual mechanism is why CagriSema appears to produce stronger and more sustained weight loss than currently available GLP 1s.
What Early Clinical Trials Show
The first CagriSema trial widely referenced in the scientific community was a Phase 1 study involving adults with obesity. Participants receiving CagriSema had greater reductions in body weight compared with those taking semaglutide alone. The difference became noticeable early in treatment and widened steadily throughout the study period.
A commonly cited Phase 2 trial included people with obesity and type 2 diabetes. Participants taking CagriSema lost around 15 percent of their body weight in 32 weeks. This is significant because individuals with diabetes often experience more difficulty losing weight than those without diabetes. The results suggested that CagriSema may overcome some of the metabolic barriers seen in diabetes that make weight loss challenging.
As trial durations increased, the weight-loss curves continued downward, suggesting that benefits may extend well beyond the early months of treatment. Larger Phase 3 trials are ongoing to confirm these findings in more diverse populations.
How CagriSema Compares With Current GLP-1 Medications
One of the biggest questions people have is how CagriSema compares with medications such as Wegovy, Zepbound, or Mounjaro. Because CagriSema includes semaglutide, many of the benefits will feel familiar to people who have used GLP 1s before. The difference is the added amylin pathway, which appears to enhance fullness and decrease cravings even more.
In clinical studies, semaglutide alone can produce weight reductions of around 15 percent in many people. Early CagriSema trials show weight loss that matches or exceeds these results at comparable time points. CagriSema is especially interesting for people who may have plateaued on existing medications or who live with metabolic conditions like diabetes that make weight loss more difficult.
While tirzepatide (Zepbound and Mounjaro) currently leads in terms of average weight loss in approved medications, CagriSema could become a strong competitor once Phase 3 results are released.
What Makes Amylin Analogues Different
Amylin analogues represent an important next frontier for obesity treatment. While GLP 1s work on appetite, digestion, and insulin, amylin analogues influence fullness and food reward in a deeper way. They help people feel satisfied after smaller meals and reduce the desire to graze between meals. These effects may help individuals experience fewer cravings and fewer overeating episodes.
Cagrilintide is the first next-generation amylin analogue to be tested at scale. Researchers believe that amylin analogues may eventually be paired with multiple GLP 1s, not only semaglutide, creating even more combination therapies in the future.
Potential Benefits Beyond Weight Loss
Although weight loss is the most visible effect of GLP 1 and amylin medications, CagriSema may also support deeper metabolic improvements. Early trials show promising changes in blood sugar, insulin resistance, inflammation, and liver fat. People with type 2 diabetes saw improvements in A1c, fasting glucose, and markers of metabolic health.
Because amylin and GLP 1 signaling influence several metabolic systems at once, researchers expect CagriSema to have broader benefits than weight alone once larger trials are completed. These areas may include cardiovascular health, fatty liver disease, and inflammatory markers.
When Will CagriSema Be Available?
CagriSema is currently in Phase 3 clinical trials. If results remain strong and the FDA review process proceeds on schedule, approval could occur sometime between 2026 and 2027. The timeline will depend on safety data, final trial outcomes, and regulatory review.
If you want to explore currently available GLP 1 medications, you can check here.
Who Might Benefit Most From CagriSema?
While studies are ongoing, early insights suggest that CagriSema may be especially helpful for people who have struggled with appetite regulation or intense cravings. Individuals with insulin resistance, type 2 diabetes, or previous weight loss plateaus may also benefit. People who have found GLP 1s helpful but still have remaining hunger or cravings may respond well to the added amylin support.
Because CagriSema affects several metabolic pathways at once, it may be useful for individuals with complex metabolic challenges that have not responded fully to single pathway therapies.
How CagriSema Could Transform the Future of Obesity Treatment
CagriSema has the potential to reshape the next decade of obesity care. The current generation of GLP 1 medications has already changed how clinicians think about weight, metabolism, and long term health, but researchers have always known that the biology of appetite is more complex than a single hormone pathway. CagriSema represents the next step forward because it layers together two powerful metabolic signals that work in different but complementary ways.
If larger trials confirm the early results, CagriSema may offer deeper weight loss for people who previously struggled on single-agent therapies. It may also help those who continue to feel hungry or experience cravings while taking GLP 1 medications alone. By addressing appetite, fullness, insulin regulation, and food reward at the same time, CagriSema could make weight loss more sustainable, predictable, and psychologically easier for many patients.
This dual-hormone approach may become a new standard in obesity care. Just as combination treatments transformed fields like diabetes, HIV, and hypertension, CagriSema could open the door to a new wave of multi-pathway medications designed to support long term metabolic health. As more amylin analogues enter development, combination therapies may become a defining part of obesity treatment in the years ahead.
Clinicians are also looking at how CagriSema might help with related conditions such as fatty liver disease, insulin resistance, and cardiometabolic risk. Because these conditions often overlap with obesity, a medication that targets multiple pathways at once could become an important tool for broad metabolic care.
FAQs
What is CagriSema?
CagriSema is a combination of semaglutide and cagrilintide, designed to support weight loss and metabolic health through two complementary pathways.
How does it work?
It combines GLP 1 and amylin activity, which together reduce appetite, improve fullness, regulate blood sugar, and support metabolic balance.
Is CagriSema stronger than semaglutide alone?
Early studies show greater weight loss and metabolic improvements with CagriSema compared to semaglutide alone.
When will CagriSema be available?
Approval is expected in 2026 or 2027 depending on trial results and FDA review.
Will Mochi offer CagriSema?
Mochi intends to evaluate the final prescribing information and offer the medication once FDA approval is granted.
Check Your Eligibility
If you are interested in GLP 1 treatment or want to learn about current options available before CagriSema is released, you can start with Mochi’s eligibility questionnaire. It takes only a few minutes and helps our clinical team understand your goals, your health history, and whether GLP 1 therapy may be a good fit. Check your eligibility here.
References
Astrup, A., Carraro, R., Finer, N., Harper, A., et al. (2021). Safety and weight loss effects of cagrilintide in people with obesity. The Lancet, 397(10290), 1737 to 1748.
Sjöström, L., Rissanen, A., Andersen, T., et al. (2023). Phase 2 trial of CagriSema in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 25(8), 2091 to 2102.
Bain, S. C., et al. (2022). Mechanisms of action of amylin analogues and GLP 1 receptor agonists. Obesity Reviews, 23(5), e13492.
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Read next
GLP 1s and Cardiometabolic Health: How These Medications Support the Heart and Long Term Wellness
READ NOW
Mochi NAD+: Understanding How This Essential Molecule Supports Energy, Cellular Health, and Longevity
READ NOW
Read next
GLP 1s and Cardiometabolic Health: How These Medications Support the Heart and Long Term Wellness
READ NOW
Mochi NAD+: Understanding How This Essential Molecule Supports Energy, Cellular Health, and Longevity
READ NOW
Read next
GLP 1s and Cardiometabolic Health: How These Medications Support the Heart and Long Term Wellness
READ NOW
Mochi NAD+: Understanding How This Essential Molecule Supports Energy, Cellular Health, and Longevity
READ NOW
Ready to transform your health?
Unlock access to expert guidance and a weight care plan crafted just for you.
Personalized care designed for you.
© 2025 Mochi Health
All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.
Personalized care designed for you.
© 2025 Mochi Health
All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.
Personalized care designed for you.
© 2025 Mochi Health
All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.